CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Dec

Today In Oncology

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

David A. Hyman, MD, JD, on Inclusive Shared Savings

Acupuncture May Improve Perceived Cognitive Difficulties in Breast Cancer Survivors

Follicular Lymphoma Durable Remissions and Sustained Safety With Third-Line Lisocabtagene Maraleucel

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Large AI Breast Cancer Screening Trial Increases Detection Rate

P-RAD Trial Shows Increased T-Cell Infiltration With Preoperative Radiation Added to Anti-PD-1 Therapy in Early Breast Cancer